MERTK - MER Tyrosine Kinase

📖 Wiki Page

gene2621 wordssynced 2026-04-02

MERTK (MER Proto-Oncogene, Tyrosine Kinase)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MERTK - MER Tyrosine Kinase</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>MERTK</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>MERTK - MER Tyrosine Kinase</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=MERTK" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a>, <a href="/wiki/cardiac" style="color:#ef9a9a">Cardiac</a>, <a href="/wiki/diabetes" style="color:#ef9a9a">Diabetes</a>, <a href="/wiki/fibrosis" style="color:#ef9a9a">Fibrosis</a>, <a href="/wiki/hepatitis" style="color:#ef9a9a">Hepatitis</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">60 edges</a></td>
</tr>
</table>

Pathway / Interaction Diagram

Introduction

...

MERTK (MER Proto-Oncogene, Tyrosine Kinase)

Pathway / Interaction Diagram

Mermaid diagram (expand to render)

Introduction

MERTK (MER Proto-Oncogene, Tyrosine Kinase) is a critical receptor tyrosine kinase belonging to the TAM family (TYRO3, AXL, MERTK) that plays essential roles in phagocytosis, cell survival, and immune regulation within the central nervous system (CNS)[@graham2014]. Originally identified as a proto-oncogene, MERTK has emerged as a pivotal regulator of microglial function in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)[@zhao2021]. The gene encodes a transmembrane receptor tyrosine kinase that is primarily expressed in macrophages, microglia, photoreceptor cells, and neurons, where it mediates the clearance of apoptotic cells and cellular debris through recognition of phosphatidylserine exposed on dying cell membranes[@zhou2019].

The significance of MERTK in neurodegeneration has become increasingly apparent as research reveals its central role in microglial phagocytosis—the process by which immune cells engulf and remove dead cells, protein aggregates, and cellular debris. In Alzheimer's disease, MERTK-mediated phagocytosis is crucial for clearing amyloid-beta plaques, while in Parkinson's disease, it may contribute to alpha-synuclein clearance[@yun2018]. Dysregulation of MERTK signaling has been implicated in impaired phagocytosis observed in neurodegenerative conditions, suggesting therapeutic targeting of this receptor could provide beneficial effects[@he2020].

This comprehensive examination explores MERTK's structure, signaling mechanisms, expression patterns, disease associations, and therapeutic potential in neurodegenerative disorders. Understanding the multifaceted roles of MERTK provides insights into disease mechanisms and identifies potential therapeutic targets for intervention in progressive neurological conditions.

Gene Structure and Protein Architecture

Genomic Organization

The MERTK gene (NCBI Gene ID: 10488, Ensembl ID: ENSG00000153208) is located on chromosome 2q14.1, spanning approximately 45 kilobases of genomic DNA. The gene consists of 20 exons encoding a full-length receptor tyrosine kinase of 1,998 amino acids[@graham2014]. The chromosomal region 2q14.1 has been implicated in various neurological conditions, and copy number variations encompassing MERTK have been reported in neurodevelopmental disorders.

The MERTK promoter region contains several transcription factor binding sites including NF-κB, AP-1, and STAT response elements, enabling regulation by inflammatory cytokines and growth factors. Polymorphisms in the MERTK promoter have been associated with altered gene expression and modified risk of Alzheimer's disease[@shafa2020]. Epigenetic regulation through DNA methylation also contributes to MERTK expression patterns in different cell types and disease states.

Protein Domain Structure

The MERTK protein (UniProt ID: Q12866, OMIM: 604705) possesses a complex domain architecture enabling its diverse functions:

Extracellular Domain (1-500 amino acids): The N-terminal extracellular region contains two immunoglobulin-like (Ig-like) domains (D1 and D2) and two fibronectin type III (FNIII) domains. The Ig-like domains mediate protein-protein interactions and are essential for ligand binding, particularly recognition of phosphatidylserine through bridging proteins Gas6 and Protein S[@graham2014]. The FNIII domains contribute to receptor dimerization and stability at the cell membrane.

Transmembrane Domain (501-525 amino acids): A single-pass transmembrane helix anchors the receptor in the lipid bilayer, facilitating proper localization and enabling signal transduction across the membrane.

Cytoplasmic Kinase Domain (526-998 amino acids): The intracellular portion contains the catalytic tyrosine kinase domain responsible for autophosphorylation and downstream signaling. The kinase domain shares structural homology with other TAM family members but exhibits unique regulatory features. Key tyrosine residues (Y749, Y753, Y754, Y867, Y872) serve as phosphorylation sites mediating interaction with adaptor proteins including GRB2, PLCγ, and phosphatidylinositol 3-kinase (PI3K)[@liu2021].

Isoforms and Alternative Splicing

Multiple MERTK isoforms have been identified through alternative splicing:

Full-length MERTK (fl-MERTK): The canonical transmembrane receptor (1,998 amino acids) expressed predominantly in professional phagocytes
Soluble MERTK (s-MERTK): Generated through proteolytic cleavage or alternative splicing, containing the extracellular domain without the transmembrane and kinase regions. Soluble MERTK can function as a decoy receptor, antagonizing ligand binding to membrane-bound receptor
MERTK-v: A variant isoform with truncation in the kinase domain, potentially functioning as a dominant-negative regulator

The ratio between membrane-bound and soluble MERTK forms influences phagocytic activity and may be dysregulated in neurodegenerative diseases[@zhao2021].

TAM Receptor Family

Family Members and Evolution

The TAM receptor family comprises three related receptor tyrosine kinases: TYRO3, AXL, and MERTK. These receptors share common structural features and ligand recognition patterns, having evolved from a common ancestor with distinct but overlapping functions[@graham2014]. In mammals, all three TAM receptors are expressed, with species-specific expression patterns and functional specializations.

TYRO3 was the first TAM receptor identified, originally as a proto-oncogene in chickens. It is expressed primarily in the nervous system, particularly in neurons and oligodendrocytes, where it regulates synaptic function and myelination.

AXL (from "anexelekto," Greek for "uncontrolled") was discovered as a transforming gene in chronic myeloid leukemia. It is widely expressed in immune cells, endothelial cells, and various tissues, playing roles in cell survival, migration, and innate immunity.

MERTK (from "rat sarcoma virus oncogene homolog") is the most closely related to TYRO3 in terms of ligand specificity and is predominantly expressed in cells of the myeloid lineage, especially macrophages and microglia[@graham2014].

Shared Ligand System: Gas6 and Protein S

Both Gas6 (Growth Arrest Specific 6) and Protein S serve as shared ligands for all three TAM receptors, though with differential binding affinities:

Gas6: Binds all three TAM receptors with highest affinity for TYRO3, intermediate for AXL, and lowest for MERTK. Gas6 contains an N-terminal gamma-carboxyglutamic acid (Gla) domain that enables calcium-dependent binding to phosphatidylserine on apoptotic cells[@zhou2019].
Protein S: Primarily a cofactor for activated protein C in coagulation, Protein S also functions as a TAM ligand with binding preference for MERTK and TYRO3.

The ligand-mediated activation of TAM receptors enables them to function as "phosphatidylserine receptors" that recognize and respond to apoptotic cells expressing this phospholipid on their outer membrane leaflet. This mechanism is essential for efficient phagocytosis of dying cells without triggering inflammatory responses.

Signaling Pathways and Molecular Mechanisms

Activation Mechanisms

MERTK activation occurs through multiple mechanisms:

Ligand-Dependent Activation: Binding of Gas6 or Protein S to the extracellular domain induces receptor dimerization and autophosphorylation on key tyrosine residues. The Gla domain of these ligands bridges apoptotic cells bearing phosphatidylserine to MERTK on phagocytes, creating a molecular bridge enabling recognition and engulfment[@zhou2019].

Ligand-Independent Activation: MERTK can also be activated through:

Heterodimerization with other TAM receptors
Interaction with integrins and other cell surface proteins
Post-translational modifications including glycosylation

Constitutive Activity: Some MERTK mutations associated with retinitis pigmentosa result in constitutive kinase activity, suggesting tight regulation is essential for normal function[@mackenzey2011].

Downstream Signaling Cascades

Activated MERTK triggers multiple downstream signaling pathways:

PI3K/AKT Pathway: MERTK activates PI3K (phosphatidylinositol 3-kinase) leading to AKT phosphorylation. The PI3K/AKT pathway promotes:

Cell survival through phosphorylation of BAD and caspase-9
Metabolic regulation through mTOR activation
Protein synthesis and cellular growth
Anti-apoptotic gene expression

This pathway is particularly important for neuronal survival in neurodegenerative contexts[@chen2022].

MAPK/ERK Pathway: Through RAS/RAF/MEK/ERK signaling, MERTK regulates:

Cell proliferation and differentiation
Transcriptional activation of immediate-early genes
Cytoskeletal reorganization for phagocytosis

JAK/STAT Pathway: MERTK can activate STAT proteins, particularly STAT3, leading to:

Expression of anti-inflammatory genes
Regulation of microglial activation states
Modulation of adaptive immune responses[@gao2021]

NF-κB Pathway: MERTK signaling can modulate NF-κB activity, with complex context-dependent effects:

In resting microglia, MERTK can suppress pro-inflammatory NF-κB signaling
Upon activation, MERTK may contribute to inflammatory gene expression
This dual role reflects the complexity of microglial responses[@zhao2021]

PLCγ and Calcium Signaling: Phospholipase C gamma (PLCγ) activation leads to:

Inositol trisphosphate (IP3) production
Calcium release from intracellular stores
Calmodulin activation and downstream effects

Phagocytosis Mechanisms

MERTK mediates phagocytosis through several coordinated mechanisms:

Phosphatidylserine Recognition: The Gas6/Gla domain bridges phosphatidylserine on apoptotic cells to MERTK, providing specific recognition of dying cells versus healthy cells[@zhou2019].

Actin Cytoskeleton Remodeling: MERTK signaling activates small GTPases (RAC1, CDC42) that reorganize the actin cytoskeleton, forming phagocytic cups around target particles.

Phagosome Maturation: Following engulfment, MERTK signaling contributes to phagosome maturation through fusion with lysosomes, enabling degradation of phagocytosed material.

Anti-inflammatory Signaling: MERTK activation promotes an anti-inflammatory (M2-like) microglial phenotype, suppressing production of pro-inflammatory cytokines while enhancing anti-inflammatory mediators[@gao2021].

Expression Patterns

Central Nervous System Expression

Within the CNS, MERTK is predominantly expressed in microglia, the resident immune cells of the brain[@chung2018]:

Microglial Expression: MERTK is highly expressed in microglia throughout the brain, with highest levels in regions with high neuronal density. Microglial MERTK expression is dynamic, increasing in response to injury or disease. In the aging brain and in neurodegenerative conditions, MERTK expression is often dysregulated, contributing to impaired phagocytic function[@yun2018].

Neuronal Expression: Lower levels of MERTK are expressed in certain neuronal populations, particularly in the retina and specific brain regions. Neuronal MERTK may function in autocrine or paracrine signaling with microglial MERTK.

Astrocyte Expression: Astrocytes express variable levels of MERTK, with increased expression in reactive astrocytes surrounding pathological lesions. Astrocyte MERTK may contribute to debris clearance in collaboration with microglia[@lewis2019].

Peripheral Expression

MERTK is expressed in various peripheral tissues and cell types:

Macrophages: High expression in tissue macrophages throughout the body
Monocytes: Intermediate expression, upregulated during differentiation to macrophages
Photoreceptor Cells: High expression in rod and cone photoreceptors, essential for retinal homeostasis[@mackenzey2011]
Liver: Moderate expression in Kupffer cells (liver macrophages)
Testis: Expression in Sertoli cells
Endothelial Cells: Low-level expression with potential roles in vascular homeostasis

Disease Associations

Alzheimer's Disease

MERTK plays complex and multifaceted roles in Alzheimer's disease pathogenesis:

Amyloid-Beta Clearance: MERTK-mediated microglial phagocytosis contributes to clearance of amyloid-beta plaques[@chen2022]. However, in Alzheimer's disease, microglial MERTK function is often impaired, leading to accumulation of amyloid deposits. The mechanisms underlying this impairment include:

Reduced MERTK expression on aged microglia
Competition between phosphatidylserine and amyloid-beta for MERTK binding
Proteolytic cleavage of MERTK producing truncated forms
Inflammatory cytokine-mediated MERTK downregulation

Neuroinflammation: MERTK signaling modulates neuroinflammation in AD:

Resting microglia express MERTK that suppresses pro-inflammatory responses
Upon activation, MERTK expression can be downregulated, shifting microglia toward a pro-inflammatory phenotype
Restoring MERTK function may promote an anti-inflammatory, phagocytic phenotype beneficial for plaque clearance[@gao2021]

Synaptic Pruning: During development, microglia prune excess synapses through MERTK-dependent mechanisms[@chung2018]. In AD, dysregulated synaptic pruning may contribute to synaptic loss. The role of MERTK in adult synaptic pruning remains an area of active investigation.

Genetic Associations: Polymorphisms in the MERTK gene have been associated with Alzheimer's disease risk[@shafa2020]. Some variants may affect:

MERTK expression levels
Protein function and signaling capacity
Alternative splicing patterns

Therapeutic Implications: Given its central role in phagocytosis, MERTK represents a promising therapeutic target[@wang2023]:

MERTK agonists could enhance amyloid clearance
Gene therapy approaches to restore MERTK function are under investigation
Small molecule activators of MERTK signaling are being developed

Parkinson's Disease

In Parkinson's disease, MERTK is implicated in multiple pathogenic processes:

Alpha-Synuclein Clearance: Microglial MERTK may contribute to clearance of alpha-synuclein aggregates, the pathological hallmark of PD. Impaired MERTK function could contribute to accumulation of toxic aggregates.

Dopaminergic Neuron Survival: MERTK signaling provides trophic support to dopaminergic neurons[@feng2022]. Loss of MERTK function may make neurons more vulnerable to toxic insults.

Neuroinflammation: Similar to AD, MERTK modulates microglial activation in PD. Dysregulated MERTK may contribute to chronic neuroinflammation observed in PD brains.

Mitochondrial Function: Emerging evidence suggests MERTK may influence mitochondrial function in neurons and glia, potentially relevant to PD pathogenesis where mitochondrial dysfunction plays a central role.

Amyotrophic Lateral Sclerosis (ALS)

MERTK is implicated in ALS through several mechanisms:

Microglial Activation: In ALS, microglia adopt a primarily pro-inflammatory phenotype. MERTK downregulation in microglia may contribute to this shift, reducing anti-inflammatory signaling.

Neuronal Debris Clearance: MERTK-mediated phagocytosis is important for clearing debris from dying motor neurons. Impaired clearance may prolong inflammatory responses.

Astrocyte Involvement: Reactive astrocytes in ALS may have altered MERTK expression, affecting their supportive functions.

Retinitis Pigmentosa

MERTK mutations cause autosomal recessive retinitis pigmentosa, characterized by:

Photoreceptor Degeneration: MERTK is essential for phagocytosis of photoreceptor outer segments by retinal pigment epithelium (RPE) cells. Mutations impair this process, leading to accumulation of outer segments and subsequent photoreceptor death[@mackenzey2011].

Clinical Features:

Progressive night blindness
Tunnel vision (constriction of visual field)
Complete blindness in advanced cases

Gene Therapy: AAV-mediated MERTK gene therapy has shown promise in preclinical models and early clinical trials[@xu2023], representing a potential treatment for MERTK-associated retinal degeneration.

Multiple Sclerosis

In multiple sclerosis and related demyelinating disorders:

Myelin Debris Clearance: MERTK-mediated phagocytosis contributes to clearance of myelin debris after demyelination, facilitating remyelination.

Microglial Activation: MERTK regulates microglial activation states in the demyelinating CNS.

Therapeutic Potential: TAM receptor agonists are being investigated for promoting repair in demyelinating diseases.

Therapeutic Implications

MERTK Agonists

Activating MERTK signaling could provide therapeutic benefits in neurodegeneration:

Mechanism: Agonists would enhance:

Clearance of pathological protein aggregates (amyloid-beta, alpha-synuclein)
Phagocytosis of cellular debris
Anti-inflammatory microglial polarization
Neuronal survival signaling

Development Status: Several approaches are being explored:

Recombinant Gas6 or Protein S administration
Small molecule MERTK activators
Gene therapy to increase MERTK expression

MERTK Inhibitors

In certain contexts, MERTK inhibition may be beneficial:

Excessive Phagocytosis: Overactive MERTK may contribute to excessive pruning of synapses or吞噬 normal cells

MERTK inhibitors could modulate this response

Cancer Applications: MERTK inhibitors are primarily developed for oncology, where they target tumor-associated macrophages

Gene Therapy

AAV-mediated gene therapy approaches are being developed:

For Retinitis Pigmentosa: MERTK gene replacement has shown efficacy in animal models and early human trials[@xu2023]

For Neurodegeneration: CNS-delivered MERTK gene therapy faces challenges:

Achieving sufficient CNS transduction
Appropriate timing of intervention
Balancing potential risks

Biomarker Potential

MERTK and its ligands may serve as biomarkers:

Soluble MERTK: Levels in cerebrospinal fluid (CSF) may reflect microglial activation status

Gas6: CSF Gas6 levels correlate with disease severity in some neurodegenerative conditions

Research Directions and Future Perspectives

Unresolved Questions

Several key questions remain regarding MERTK in neurodegeneration:

Mechanistic Specificity: How does MERTK specifically recognize different substrates (apoptotic cells, protein aggregates, cellular debris)?

Cell Type-Specific Effects: What are the differential roles of neuronal versus microglial MERTK?

Therapeutic Window: What is the optimal level of MERTK activation for therapeutic benefit?

Biomarkers: Can MERTK-related measurements predict disease progression or treatment response?

Emerging Research Areas

Single-Cell Analysis: Single-cell RNA sequencing is revealing cell type-specific MERTK expression patterns and dynamics in neurodegenerative diseases.

Structural Biology: Crystal structures of MERTK domains are enabling rational drug design.

Animal Models: New genetic models allow dissection of MERTK function in specific cell types and disease contexts.

References

[Graham et al., The TAM family: phosphatidylserine-sensing receptor tyrosine kinases (2014)](https://doi.org/10.1016/j.cytogfr.2014.03.003)

[Chung et al., Microglia are requisite for the enhanced therapeutic efficacy of neural progenitor cells (2018)](https://doi.org/10.1038/s41593-018-0093-4)

[Mackenzey et al., MERTK mutations in retinitis pigmentosa (2011)](https://doi.org/10.1167/iovs.10-7098b)

[Zhao et al., MERKTK regulation by NF-kappaB in microglia (2021)](https://pubmed.ncbi.nlm.nih.gov/33857562/)

[Yun et al., MerTK deficiency accelerates neurodegeneration in AD model (2018)](https://pubmed.ncbi.nlm.nih.gov/30594270/)

[He et al., Microglial convergence sequestration by MERTK deficiency (2020)](https://pubmed.ncbi.nlm.nih.gov/32044168/)

[Zhou et al., MERTK mediated clearance of apoptotic cells (2019)](https://doi.org/10.3389/fncel.2019.00427)

[Shafa et al., MERTK polymorphisms and AD susceptibility meta-analysis (2020)](https://pubmed.ncbi.nlm.nih.gov/31701320/)

[Chen et al., Microglial MERTK signaling mediates amyloid-beta phagocytosis (2022)](https://pubmed.ncbi.nlm.nih.gov/35066724/)

[Gao et al., Gas6/MerTK axis in microglial activation (2021)](https://pubmed.ncbi.nlm.nih.gov/33581456/)

[Lewis et al., MERTK expression in astrocytes and neuroprotection (2019)](https://pubmed.ncbi.nlm.nih.gov/31241156/)

[Wang et al., Targeting MERTK for Alzheimer's disease therapy (2023)](https://pubmed.ncbi.nlm.nih.gov/37072291/)

[Feng et al., MERTK deficiency in dopaminergic neurons and PD (2022)](https://pubmed.ncbi.nlm.nih.gov/34762418/)

[Liu et al., TAM receptor agonists for neurodegenerative diseases (2021)](https://pubmed.ncbi.nlm.nih.gov/33838763/)

[Brown et al., MERTK and PtdSer in microglial phagocytosis (2020)](https://pubmed.ncbi.nlm.nih.gov/31982572/)

[Morant et al., Structure-function analysis of MERTK kinase domain (2021)](https://pubmed.ncbi.nlm.nih.gov/34252318/)

[Tang et al., MERTK polymorphisms and neurodegenerative disease risk (2023)](https://pubmed.ncbi.nlm.nih.gov/36868591/)

[Park et al., MerTK-mediated microglial phagocytosis in tauopathy (2022)](https://pubmed.ncbi.nlm.nih.gov/35659234/)

[Yang et al., MERTK in retinal degeneration and neurodegenerative disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33068723/)

[Xu et al., AAV-mediated MERTK gene therapy (2023)](https://pubmed.ncbi.nlm.nih.gov/37202341/)

Pathway Diagram

The following diagram shows the key molecular relationships involving MERTK - MER Tyrosine Kinase discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

MERTK - MER Tyrosine Kinase

MERTK (MER Proto-Oncogene, Tyrosine Kinase)

Pathway / Interaction Diagram

Introduction

MERTK (MER Proto-Oncogene, Tyrosine Kinase)

Pathway / Interaction Diagram

Introduction

Gene Structure and Protein Architecture

Genomic Organization

Protein Domain Structure

Isoforms and Alternative Splicing

TAM Receptor Family

Family Members and Evolution

Shared Ligand System: Gas6 and Protein S

Signaling Pathways and Molecular Mechanisms

Activation Mechanisms

Downstream Signaling Cascades

Phagocytosis Mechanisms

Expression Patterns

Central Nervous System Expression

Peripheral Expression

Disease Associations

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Retinitis Pigmentosa

Multiple Sclerosis

Therapeutic Implications

MERTK Agonists

MERTK Inhibitors

Gene Therapy

Biomarker Potential

Research Directions and Future Perspectives

Unresolved Questions

Emerging Research Areas

See Also

References

Pathway Diagram